Lurbinectedin is a chemotherapy drug that has shown promise in enhancing the efficacy of immunotherapy in certain cancers. According to DrugPatentWatch , Lurbinectedin is a synthetic compound derived from marine organisms and is currently in clinical trials for various types of cancer. The drug works by inhibiting the transcription process of cancer cells, which leads to cell death.
A study published in Frontiers in Oncology  investigated the potential of combining Lurbinectedin with immunotherapy in the treatment of small cell lung cancer (SCLC). The study found that Lurbinectedin enhances the efficacy of immune checkpoint inhibitors (ICIs) by increasing the infiltration of T cells into the tumor microenvironment. The combination of Lurbinectedin and ICIs resulted in improved antitumor activity and prolonged survival in preclinical models of SCLC.
Another study published in the Journal of Clinical Oncology  investigated the combination of Lurbinectedin with pembrolizumab, an immune checkpoint inhibitor, in patients with advanced solid tumors. The study found that the combination therapy was well-tolerated and showed promising antitumor activity, with an overall response rate of 33%.
In conclusion, the available evidence suggests that Lurbinectedin has the potential to enhance the efficacy of immunotherapy in certain cancers, particularly when combined with immune checkpoint inhibitors. However, further clinical trials are needed to fully evaluate the safety and efficacy of this combination therapy.